The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

Leukemia

Volumn 22, Issue 9, 2008, Pages 1728-1736

  Kojima, K ^a   Shimanuki, M ^a   Shikami, M ^b   Samudio, I J ^c   Ruvolo, V ^c   Corn, P ^c   Hanaoka, N ^a   Konopleva, M ^c   Andreeff, M ^c   Nakakuma, H ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; CASPASE 3; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NUTLIN 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; SURVIVIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; MITOCHONDRION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEPHOSPHORYLATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; WILD TYPE;

APOPTOSIS; DRUG SYNERGISM; FURANS; GENE EXPRESSION REGULATION; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; MITOCHONDRIAL PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIDINES; PYRIMIDINES; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 51649098950     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.158     Document Type: Article

References (45)

1. Parcellier A, Tintignac LA, Zhuravleva E, Hemmings BA. PKB and the mitochondria: AKTing on apoptosis. Cell Signal 2008; 20: 21-30.
2. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006; 25: 6416-6422.
3. Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006; 20: 911-928.
4. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18: 77-82.
5. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005; 9: 59-71.
6. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972-980.
7. Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its significance as a prognostic variable. Leukemia 2003; 17: 995-997.
8. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinaselAkt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, MAPkinase and p53 pathways. Leukemia 2005; 19: 586-594.
9. Bardet V, Tamburini J, Ifrah N, Dreyfus F, Mayeux P, Bouscary D et al Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica 2006; 91: 757-764.
10. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M et al Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108: 2358-2365.
11. Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broöt P et al Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 2007; 110: 1025-1028.
12. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
13. Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A et al. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer 2000; 89: 1976-1982.
14. Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, Störkel S et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol 1996; 57: 230-240.
15. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 1993; 82: 2617-2623.
16. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003; 1: 1001-1008.
17. Wong S, McLaughlin J, Cheng D, Zhang C, Shokat KM, Witte ON. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci USA 2004; 101: 17456-17461.
18. Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M. MEK inhibition enhances nuclear proapoptotic function of p53 in AML cells. Cancer Res 2007; 67: 3210-3219.
19. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10 375-388.
20. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L et al Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: Rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379-382.
21. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9: 341-349.
22. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
23. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106: 3150-3159.
24. Verhaegen M, Bauer JA, Martín de la Vega C, Wang G, Wolter KG, Brenner JC et al. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 2006; 66: 11348-11359.
25. Kojima K, Konopleva M, McQueen T, O'brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108: 993-1000.
26. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005; 309: 1732-1735.
27. Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 1999; 144: 891-901.
28. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell Cycle 2006; 5: 2778-2786.
29. Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ et al. Phosphorylation of HDM2 by Akt. Oncogene 2002; 21: 1955-1962.
30. Pause A, Belsham GJ, Gingras AC, Donzé O, Lin TA, Lawrence Jr JC et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 1994; 371: 762-767.
31. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8: 179-183.
32. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
33. Tirado OM, Mateo-Lozano S, Notario V. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax: Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity. Oncogene 2005; 24: 3348-3357.
34. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L et al Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006; 66: 6589-6597.
35. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120: 747-759.
36. Yamaguchi H, Wang HG. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001; 20: 7779-7786.
37. Arokium H, Ouerfelli H, Velours G, Camougrand N, Vallette FM, Manon S. Substitutions of potentially phosphorylatable serine residues of bax reveal how they may regulate its interaction with mitochondria. J Biol Chem 2007; 282: 35104-35112.
38. Horton LE, Bushell M, Barth-Baus D, Tilleray VJ, Clemens MJ, Hensold JO. p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation. Oncogene 2002; 21: 5325-5334.
39. Tilleray V, Constantinou C, Clemens MJ. Regulation of protein synthesis by inducible wild-type p53 in human lung carcinoma cells. FEBS Lett 2006; 580: 1766-1770.
40. Herbert TP, Tee AR, Proud CG. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem 2002; 277: 11591-11596.
41. Chow S, Minden MD, Hedley DW. Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol 2006; 34: 1183-1191.
42. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J et al. Targeting survival cascades induced by activation of Ras/ Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22: 708-722.
43. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001; 108: 851-859.
44. Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A. Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 2007; 7: 310-318.
45. Park S, Chapuis N, Bardet V, Willems L, Tamburini J, Knight ZA et al PI-103, a dual inhibitor of class I phosphatidylinositide 3-kinase and mTOR, has anti-leukemic activity in acute myeloid leukemia. Blood 2007; 110: 268a. [Abstract #876].